TY - JOUR
T1 - Serum testosterone level as possible predictive marker in androgen receptor axis-targeting agents and taxane chemotherapies for castration-resistant prostate cancer
AU - Shiota, Masaki
AU - Kashiwagi, Eiji
AU - Murakami, Tomohiko
AU - Takeuchi, Ario
AU - Imada, Kenjiro
AU - Inokuchi, Junichi
AU - Tatsugami, Katsunori
AU - Eto, Masatoshi
N1 - Funding Information:
We would like to thank Edanz Group Japan for editorial assistance. This work was supported by JSPS KAKENHI (grant no. 17K11145 ), Medical Research Promotion Grant from Takeda Science Foundation , and Research Promotion Grant from Shin-Nihon Foundation of Advanced Medical Research .
Publisher Copyright:
© 2018 Elsevier Inc.
PY - 2019/3
Y1 - 2019/3
N2 - Purpose: Currently, several therapeutic options for castration-resistant prostate cancer (CRPC) are available, for which predictive biomarkers have not been established. Therefore, we aimed to reveal the association between pretreatment serum testosterone level and antitumor outcomes when treated with androgen receptor axis-targeting agents and taxane chemotherapies for CRPC. Patients and methods: The present study included Japanese patients with metastatic prostate cancer whose serum testosterone levels during androgen-deprivation therapy were available. The antitumor outcomes when treated with enzalutamide, abiraterone, docetaxel, and cabazitaxel with clinicopathological parameters including serum testosterone levels during androgen-deprivation therapy, as well as prognoses including progression-free survival and overall survival, were examined. Results: Progression-free survival among men with higher serum testosterone level was superior to that among men with lower serum testosterone level when treated with enzalutamide. On the contrary, progression-free survival and overall survival among men with higher serum testosterone level were significantly inferior to those among men with lower serum testosterone level when treated with docetaxel and cabazitaxel, respectively. Conclusions: The present study indicated distinct prognostic values of serum testosterone level when treated with androgen receptor axis-targeting agent and taxane chemotherapy for CRPC, suggesting that serum testosterone level may be useful predictive biomarker to navigate the appropriate therapy in patients with CRPC.
AB - Purpose: Currently, several therapeutic options for castration-resistant prostate cancer (CRPC) are available, for which predictive biomarkers have not been established. Therefore, we aimed to reveal the association between pretreatment serum testosterone level and antitumor outcomes when treated with androgen receptor axis-targeting agents and taxane chemotherapies for CRPC. Patients and methods: The present study included Japanese patients with metastatic prostate cancer whose serum testosterone levels during androgen-deprivation therapy were available. The antitumor outcomes when treated with enzalutamide, abiraterone, docetaxel, and cabazitaxel with clinicopathological parameters including serum testosterone levels during androgen-deprivation therapy, as well as prognoses including progression-free survival and overall survival, were examined. Results: Progression-free survival among men with higher serum testosterone level was superior to that among men with lower serum testosterone level when treated with enzalutamide. On the contrary, progression-free survival and overall survival among men with higher serum testosterone level were significantly inferior to those among men with lower serum testosterone level when treated with docetaxel and cabazitaxel, respectively. Conclusions: The present study indicated distinct prognostic values of serum testosterone level when treated with androgen receptor axis-targeting agent and taxane chemotherapy for CRPC, suggesting that serum testosterone level may be useful predictive biomarker to navigate the appropriate therapy in patients with CRPC.
UR - http://www.scopus.com/inward/record.url?scp=85056347281&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85056347281&partnerID=8YFLogxK
U2 - 10.1016/j.urolonc.2018.10.020
DO - 10.1016/j.urolonc.2018.10.020
M3 - Article
C2 - 30446464
AN - SCOPUS:85056347281
SN - 1078-1439
VL - 37
SP - 180.e19-180.e24
JO - Seminars in Urology
JF - Seminars in Urology
IS - 3
ER -
